Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer. Malchers F, Nogova L, van Attekum MH, Maas L, Brägelmann J, Bartenhagen C, Girard L, Bosco G, Dahmen I, Michels S, Weeden CE, Scheel AH, Meder L, Golfmann K, Schuldt P, Siemanowski J, Rehker J, Merkelbach-Bruse S, Menon R, Gautschi O, Heuckmann JM, Brambilla E, Asselin-Labat ML, Persigehl T, Minna JD, Walczak H, Ullrich RT, Fischer M, Reinhardt HC, Wolf J, Büttner R, Peifer M, George J, Thomas RK. J Clin Invest. 2023 Nov 1;133(21):e170217. doi: 10.1172/JCI170217.
Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus. Hoppe S, Meder L, Gebauer F, Ullrich RT, Zander T, Hillmer AM, Buettner R, Plum P, Puppe J, Malter W, Quaas A. Cancers (Basel). 2022 Sep 30;14(19):4789. doi: 10.3390/cancers14194789.
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors. Borchmann S, Selenz C, Lohmann M, Ludwig H, Gassa A, Brägelmann J, Lohneis P, Meder L, Mattlener J, Breid S, Nill M, Fassunke J, Wisdom AJ, Compes A, Gathof B, Alakus H, Kirsch D, Hekmat K, Büttner R, Reinhardt HC, Hallek M, Ullrich RT.J Immunother Cancer. 2022 Oct;10(10):e004781. doi: 10.1136/jitc-2022-004781.
SQSTM1/p62 promotes miR-198 loading into extracellular vesicles and its autophagy-related secretion. Yu X, Eischeid-Scholz H, Meder L, Kondylis V, Büttner R, Odenthal M. Hum Cell. 2022 Nov;35(6):1766-1784. doi: 10.1007/s13577-022-00765-7. Epub 2022 Sep 1.
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling CD, Nieper P, Feldmann T, Merkel O, Lorsy E, da Palma Guerreiro A, von Jan J, Kisis I, Wasserburger E, Claasen J, Faitschuk-Meyer E, Altmüller J, Nürnberg P, Yang TP, Lienhard M, Herwig R, Kreuzer KA, Pallasch CP, Buettner R, Schäfer SC, Hartley J, Abken H, Peifer M, Kashkar H, Knittel G, Eichhorst B, Ullrich RT, Herling M, Reinhardt HC, Hallek M, Schweiger MR, Frenzel LP. Blood. 2022 Jun 15:blood.2021014304. doi: 10.1182/blood.2021014304. Online ahead of print. PMID: 35704690
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I.Brägelmann J, Lorenz C, Borchmann S, Nishii K, Wegner J, Meder L, Ostendorp J, Ast DF, Heimsoeth A, Nakasuka T, Hirabae A, Okawa S, Dammert MA, Plenker D, Klein S, Lohneis P, Gu J, Godfrey LK, Forster J, Trajkovic-Arsic M, Zillinger T, Haarmann M, Quaas A, Lennartz S, Schmiel M, D'Rozario J, Thomas ES, Li H, Schmitt CA, George J, Thomas RK, von Karstedt S, Hartmann G, Büttner R, Ullrich RT, Siveke JT, Ohashi K, Schlee M, Sos ML. Nat Commun. 2021 Sep 17;12(1):5505. doi: 10.1038/s41467-021-25728-8.PMID: 34535668
Pericentromeric Satellite III transcripts induce etoposide resistance.Kanne J, Hussong M, Isensee J, Muñoz-López Á, Wolffgramm J, Heß F, Grimm C, Bessonov S, Meder L, Wang J, Reinhardt HC, Odenthal M, Hucho T, Büttner R, Summerer D, Schweiger MR. Cell Death Dis. 2021 May 24;12(6):530. doi: 10.1038/s41419-021-03810-9. PMID: 34031359
Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.Macheleidt IF, Dalvi PS, Lim SY, Meemboor S, Meder L, Käsgen O, Müller M, Kleemann K, Wang L, Nürnberg P, Rüsseler V, Schäfer SC, Mahabir E, Büttner R, Odenthal M.Mol Oncol. 2018 Nov;12(11):1965-1979. doi: 10.1002/1878-0261.12382. Epub 2018 Oct 13. PMID: 30220105